The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2024 | Advancements and challenges in bispecific antibodies for the treatment of B-NHL
Paolo Strati, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the evolving treatment landscape for B-cell non-Hodgkin lymphoma (B-NHL), highlighting advancements with anti-CD3/CD20 bispecific antibodies. Despite these innovations improving response rates, challenges such as low durable remission rates and the need for better biomarkers persist. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consulting or Advisory Role: Genentech/Roche, ADC Therapeutics, TG Therapeutics, Kite, a Gilead company. Research Funding: AstraZeneca, ALX Oncology, Gilead Sciences. Travel, Accommodations, Expenses: SOBI.
